Open AccessTHE PROBLEM OF NEUROENDOCRINE DYSFUNCTIONS IN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER (literature review)
Author(s) -
Valerii Pidkorytov,
O. I. Syerikova,
Olga Serikova,
N. A. Baybarak,
S. A. Ukrayinskyy,
О. V. Skrynnik
Publication year - 2016
Publication title -
problemi endokrinnoï patologìï
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 2
eISSN - 2518-1432
pISSN - 2227-4782
DOI - 10.21856/j-pep.2016.3.11
Subject(s) - schizoaffective disorder , schizophrenia (object oriented programming) , metabolic syndrome , medicine , psychosis , psychiatry , diabetes mellitus , disease , thyroid , pediatrics , psychology , endocrinology
Neuroendocrine dysfunctions (NED) are often observed in patients with schizophrenia spectrum disorders and could be a component of the etiopathogenesis of the disease as well as effect associated with use of atypical neuroleptics. The most common NED symptoms and syndromes are described in the literature review: neuroleptic-induced hyperprolactinemia syndrome, the frequency of occurrence 2–100 %, metabolic syndrome — a 49.3 %, increasing in body weight (neuroleptics obesity) — 40–92 %, diabetes mellitus type 2 — 6.2–25.0 %, violation of thyroid metabolism — 20–49 %, a polymorphic syndrome — 9.9–32.9 %. Metabolic syndrome is more often observed in patients with schizoaffective disorder than in patients with schizophrenia; however, explanatory factors of this association deserve further research. Patients, receiving atypical neuroleptics, must undergo regular endocrinological examination and psychiatrists must draw attention to the endocrinological component of the patient’s health. Diabetologists and psychiatrists must work together to monitor patients treated with atypical antipsychotics, with the aim of identifying their impaired glucose tolerance and diabetes management.